
Biology of High-Risk Chronic Lymphocytic Leukemia

Massimo Massaia

SC Ematologia - AO S. Croce e Carle – Cuneo, Italy Laboratorio di Immunologia dei Tumori del Sangue, CeRMS - Torino, Italy

Unmet challenges in high risk hematological malignancies: from benchside to clinical practice (2nd edition) Turin, September 13-14, 2021



AO S.Croce e Carle Cuneo

Università di Torino

Molecular Biotechnology Center





2nd edition Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Scientific board: Marco Ladetto (Alessandria) Umberto Vitolo (Candiolo-TO)

Turin, September 13-14, 2021 Starhotels Majestic

Disclosures of NAME SURNAME

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
AbbVie						x	
Roche						x	
Janssen						x	
Sanofi						x	



				1-800-4-0
ABOUT CANCER	CANCER TYPES	RESEARCH	GRANTS & TRAINING	NEWS & EVENTS

high-risk cancer ↓)(hy-risk KAN-ser)


Cancer that is likely to recur (come back), or spread.

Why does cancer recur or spread?

• standard treatments are inadequate in the short or long run;

Why current treatments are inadequate?


- unable to fully abrogate mechanisms of disease progression;
- CLL is heterogenous clonal disease under continuous evolution;




Condoluci A, et al., J Natl Compr Canc Netw. 2020 Dec 31;19(2):227-233.

CLL paradigm shift

progressive accumulation of functionally incompetent lymphocytes





Gruber M et al., *Nature.* 2019 Jun;570(7762):474-479

Burger et al., Blood. 2009;114:3367-3375

Drivers of disease progression in CLL:


Intrinsic drivers:

- genetic instability
- BCR (IGHV-M/UM)
- genetic abnormalities
- epigenetic alterations


Extrinsic drivers:

• treatments 📲

• microenvironment interactions




Drivers of disease progression in CLL:




Innate high-risk (primary)


Drivers of disease progression in CLL:



TP53 aberrations in CLL




Mechanisms for p53 mutation-associated chemotherapy resistance




Cao X et al., Drug Resist Updat. 2020 Mar;49:100671.

CLL cell interactions in the TME



Wiestner A. Haematologica. 2015 Dec;100(12):1495-507


Prognostic significance of IgVH mutational status in CLL



Damle RN et al., Blood 94: 1840-1847, 1999


Hamblin TJ et al., *Blood* 94: 1848-1854, 1999

Characteristics of U-CLL and M-CLL patient subsets




Ten Hacken E et al., *Leukemia*. 2019 Feb;33(2):287-298.

Distinct mutational landscapes by WGS in IGHV-M and IGHV-UM CLL




Burns et al., Leukemia (2018) 32, 332-342



Cavallari M et al., Oncotarget. 2018 Sep 28;9(76):34398-34412.

The IGHV mutations status is determined by the proliferation rate


nonhomology end-joining (NHEJ) repair \rightarrow low fidelity mechanism




homology-directed repair (HDR) \rightarrow high fidelity mechanism

Rozovski U, et al. Acta Haematol. 2018;140(1):51-54.

Immunogenicity potential of IGHV-derived neoantigens generated by SHM




Xu-Monette ZY et al., J Immunother Cancer. 2019 Oct 22;7(1):272.




adapted from Schreiber RD et al, Science. 2011; 331:1565-70

Clonal selection is driven by different treatment regimens.



Modified from Campo E et al. Haematologica. 2018 Dec;103(12):1956-1968

CIT-induced clonal expansion of *TP53 mutants*




Landau DA et al., *Nature*. 2015 Oct 22;526(7574):525-30.


Rossi D et al., *Blood*. 2014 Apr 3;123(14):2139-47

Malcikova J et al., Blood. 2021 May 4; pub ahead of print


Alternative clonal evolution models to survive in the TME



Clonal evolution model




Korolev KS et al., Nat Rev Cancer. 2014 May;14(5):371-80.



Modified from Campo E et al. Haematologica. 2018 Dec;103(12):1956-1968

Effects of TP53 mutations



Wild-type p53

Wild-type (WT) p53 is a tetrameric transcription factor.

DNE mutant/ wild type

wт

МΤ

X


Mutation in one allele can cause DNEs in which the mutant (MT) dimer poisons the wild-type dimer.

p53 LOF mutant

An all-mutant tetramer may have LOF of wild-type activity.


p53 GOF mutant

All-mutant tetramers may show GOF through new protein interactions with protein X.



Lane DP. Et al., Science. 2019 Aug 9;365(6453):539-540.

Mutant p53 modifies the TME to suppress immune responses




Agupitan AD et al., Int J Mol Sci. 2020 May 13;21(10):3452.


Precision Medicine



Precision Immunology




The long road of genetic advances with a clinical impact on CLL




Cuneo A et al., Haematologica. 2021 Jan 1;106(1):7-9.

The evolutionary concept of high-risk CLL




Paradigm shift of high-risk concept in CLL



adapted from Parikh, S.A. et al., Leukemia 34, 1979-1983 (2020)


Targeted therapy is not exempted from acquired resistance ibrutinib venetoclax



Zhang SQ et al., ,Br J Haematol. 2015 Aug;170(4):445-56.

modified from Thangavadivel S et al., Cancer Discov. 2019 Mar;9(3):320-322.

Dismal prognosis of CLL pts resistant to BTKi and venetoclax



Lew TE et al., Blood Adv. 2021 Sep 3:. Epub ahead of print. PMID: 34478505.

Final Thoughts:

- High-risk CLL cannot be cured by CIT
- Therapeutic switch from CIT to TT to (C)IT to IT/TT
- High-risk is an evolving concept
- Decoding mechanisms of disease progression
- Decoding mechanisms of primary and acquired drug resistance

2nd edition Unmet challenges in high risk hematological malignancies: from benchside to clinical practice 3rd edition Towards meeeting unmet challenges in high-risk CLL





Main Topics

- Targeting tumor cells
- Targeting immune cells and bystander cells
- Antibody-drug conjugates
- Bispecific antibodies
- Abscopal effect of radiotherapy
- CAR-T cells, NK, and γδ T cells
- Targeting the microbioma
- Cancer immunometabolism
- 3D cell culture models
- Mechanisms of immune resistance
- Immune lessons from allogeneic transplantation
- Tumor vaccination: back to the future

ER Congressi https://ccitc2021.it